戻る
「早戻しボタン」を押すと検索画面に戻ります。

今後説明を表示しない

[OK]

コーパス検索結果 (1語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 , we report the development of a recombinant chimeric antibody (Ab-1) against basigin, an erythrocyte
2          Anti-CD28-PV1-IgG3, a hamster-mouse chimeric antibody against murine CD28, which does not pr
3 ng murine mAbs were expressed as mouse-human chimeric antibodies and evaluated in the guinea pig mode
4 plied the analysis to a set of humanized and chimeric antibodies and to human germline sequences.
5 hich makes humanized antibody or human-mouse chimeric antibody available for clinical trials, signifi
6 nsfer of tumor-specific T cells that express chimeric antibody-based receptors (CAR) to mice with pri
7                                          The chimeric antibody (cAb 26-2F) binds to Ang and inhibits
8 orrelation between results obtained with the chimeric antibody calibrators and the positive human pla
9 d a germ-line heavy-chain/mature light-chain chimeric antibody complexed with HIV-1 gp120.
10                                              Chimeric antibodies composed of heavy and light chains,
11 f-life, we have investigated two families of chimeric antibodies, composed of identical murine heavy
12           AFM13 is a bispecific, tetravalent chimeric antibody construct (TandAb) designed for the tr
13                                The resulting chimeric antibody, designated SGN-30, retained the bindi
14                                          The chimeric antibodies exhibited immunoreactivity and affin
15                         Z2D3 is a monoclonal chimeric antibody fragment that is directed against a pr
16                       Examination of the IgM chimeric antibodies in the IMx Toxo IgM assay revealed t
17 To investigate this question, we constructed chimeric antibodies in which the human IgG1 constant reg
18 the safety and efficacy of Rituxan anti-CD20 chimeric antibody in combination with standard-dose syst
19                 To mimic IgG opsonization, a chimeric antibody-like molecule, containing human IgG1 F
20  develop anaphylaxis to basiliximab or other chimeric antibodies may be candidates for treatment with
21 70-specific antibody (FR70) or IgG1 or IgG2a chimeric antibodies on days 0, 2, 4, and 6 posttransplan
22 llogeneic donor-derived T cells expressing a chimeric antibody receptor (CAR) specific to the B-cell
23 a high-affinity immunoglobulin G(1) (IgG(1)) chimeric antibody recognizing an N-linked carbohydrate e
24 cells have been most widely used, led by the chimeric antibody rituximab, now used in nearly all type
25 ht chain from VRC01, half of the heavy chain chimeric antibodies showed substantial neutralization po
26 the context of chronic autoimmunity, we used chimeric antibodies specific for DC inhibitory receptor
27 d antibody, DMB5F3, we created a recombinant chimeric antibody that bound a panel of MUC1+ cancer cel
28                                 Rituximab, a chimeric antibody that targets CD20(+) B cells, produces
29 ith the loss of immature B cells bearing 2F5 chimeric antibodies to central tolerance mechanisms.
30    The antibody, rituximab, is a mouse/human chimeric antibody to human CD20 antigen.
31                                InflixiMAB, a chimeric antibody to human TNF-alpha, was recently appro
32 eptor (FcRB) to delay saturation of human or chimeric antibodies via differential catabolism of antig
33       No quantifiable immune response to the chimeric antibody was detected.
34                         The plant-expressed, chimeric antibody was purified and biochemically charact
35 factor (bGCSF) results in a stably expressed chimeric antibody, which proliferates mouse NFS-60 cells
36 ha or PDGFR-beta with a specific mouse/human chimeric antibody will modulate flow-induced neointimal

WebLSDに未収録の専門用語(用法)は "新規対訳" から投稿できます。